- Home
- JILL vs PRLD Comparison
JILL vs PRLD Comparison
Compare JILL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JILL | PRLD |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.1M | 207.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JILL | PRLD |
|---|---|---|
| Price | $15.64 | $3.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $18.50 | $4.67 |
| AVG Volume (30 Days) | 37.4K | ★ 316.0K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | 3.98 | ★ 23.21 |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $610,857,000.00 | $12,140,000.00 |
| Revenue This Year | $0.10 | $320.10 |
| Revenue Next Year | $2.22 | $100.00 |
| P/E Ratio | $7.73 | ★ N/A |
| Revenue Growth | 1.02 | ★ 73.43 |
| 52 Week Low | $13.32 | $0.61 |
| 52 Week High | $20.10 | $4.19 |
Technical Indicators
Market Signals| Indicator | JILL | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 54.67 |
| Support Level | $14.68 | $1.02 |
| Resistance Level | $15.84 | $4.10 |
| Average True Range (ATR) | 0.60 | 0.33 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 20.32 | 41.78 |
Price Performance
Historical ComparisonAbout JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.